GSK @gsk.com · 14/09/2026#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer. Learn more: gsk.to/4cJsjhu 011
GSK @gsk.com · 13/09/2026#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline. Learn more: gsk.to/4xrKoZ1 002
GSK @gsk.com · 10/09/2026#News for #Investors and #Media: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new prefilled syringe presentation of one of our vaccines. Learn more: gsk.to/4xMvugV 000
GSK @gsk.com · 09/09/2026The data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together. #ERSCongress 010
GSK @gsk.com · 05/09/2026We believe the future of respiratory care needs to be as diverse as the patients living with respiratory disease, supporting real-world use with longer-acting solutions that aim to offer greater choice and improve adherence. 030
GSK @gsk.com · 01/09/2026#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII. Learn more: gsk.to/4iDDU5g 000
GSK @gsk.com · 24/08/2026#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB). This approval reflects continued commitment to progress in liver disease research. Learn more: gsk.to/45Goq9d 010
GSK @gsk.com · 24/08/2026#News for #Investors and #Media: Today we announced that the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: gsk.to/3U5ph0D 000
GSK @gsk.com · 29/07/2026Yesterday we announced we will be establishing a new flagship R&D centre on the Cambridge Biomedical Campus. Learn more gsk.to/4be2p4M 020
GSK @gsk.com · 29/07/2026#News for #Investors and #Media: At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, ViiV Healthcare. 👉 Find out more: gsk.to/44YUip5 020
GSK @gsk.com · 28/07/2026Our global survey findings reveal ongoing misunderstandings about chronic hepatitis B (CHB), including gaps in awareness about prevention and its link to liver cancer. On #WorldHepatitisDay, learn more about the realities of living with CHB: gsk.to/4pG6Pai 040
GSK @gsk.com · 28/07/2026Today we’re announcing a £400 million investment in UK life sciences including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D 020
GSK @gsk.com · 28/07/2026Please read the ‘Guidance and outlooks, assumptions and cautionary statements’ on pages 52-53 of the Q2 press release. Certain non-IFRS measures are defined on pages 50-51 of the Q2 press release. 000
GSK @gsk.com · 28/07/2026News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge. Find out more: gsk.to/45qwVVv #Q2Results $GSK 111
GSK @gsk.com · 28/07/2026#News for #investors and #media: Today our licensor Hansoh Pharma announced another positive pivotal dataset on an investigational antibody-drug conjugate in our oncology pipeline. Learn more: gsk.to/45w7cLi 000
GSK @gsk.com · 27/07/2026#News for #Investors and #Media: We are announcing new data from the first randomised head-to-head study comparing daily oral 2-drug regimen vs 3-drug regimen in treatment-naïve adults at #AIDS2026. Find out more in the press release gsk.to/44QBFUg 000
GSK @gsk.com · 22/07/2026#News for #Investors and #Media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one our therapies to treat ROS1-positive non-small cell lung cancer. Learn more: gsk.to/4yButJ9 000
GSK @gsk.com · 21/07/2026#News for #Investors and #Media: We’ll be at #AIDS2026 with ViiV Healthcare, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline. 👉 Find out more in the press release: gsk.to/4fdROcs 001
GSK @gsk.com · 20/07/2026#News for #Media and #Investors: Today we announced that the EMA has accepted our submission to update the label of one of our meningococcal vaccines. If approved, this could enable a 1-dose booster for certain individuals. Learn more: gsk.to/4wf6det 000
GSK @gsk.com · 16/07/2026#News for #Investors and #Media: Today marks another step forward for a GSK-developed vaccine candidate. This significant step reinforces our commitment to partnerships that help improve global public health. Learn more: gsk.to/3T0EVd6 000
GSK @gsk.com · 15/07/2026#News for #investors and #media: Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/44vsRTI 000
GSK @gsk.com · 13/07/2026#News for #Media and #Investors: We’re excited to announce interim positive headline results from one of our clinical trial evaluating our immuno-oncology therapies. More here: gsk.to/4w59dKg 010
GSK @gsk.com · 10/07/2026#News for #Investors and #Media: Today, our licensor Hansoh Pharma announced pivotal data on an investigational antibody-drug conjugate in our oncology pipeline for the treatment cancers with high unmet needs. Learn more: gsk.to/4vpmVGN 000
GSK @gsk.com · 17/06/2026#News for #Media and #Investors: The FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs). With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives. Learn more: gsk.to/44gOOFG 000
GSK @gsk.com · 12/06/2026Our new website, YourCancerOurChallenge.com, provides education and resources to support patients impacted by ovarian and endometrial cancers, myelofibrosis and multiple myeloma, from diagnosis and beyond. Discover the patient-driven tools we’re bringing to the community: bit.ly/4vMHjCl 000
GSK @gsk.com · 12/06/2026#News for #Investors and #Media: Today we announced that the US FDA and the EMA have granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome. Learn more: gsk.to/444M6Da 000
GSK @gsk.com · 10/06/2026A child’s first steps. Dinner with old friends. What moments – big or small – matter to you? 🧡 Driven by our deep understanding of the root causes of disease, we’re accelerating our R&D in areas where we can make the most meaningful difference to patients. 🔗 gsk.to/3PPoNtO 061
GSK @gsk.com · 09/06/2026We’ve announced an agreement to acquire Nuvalent, Inc. Find out more: gsk.to/4vC0wGv 000
GSK @gsk.com · 02/06/2026That's a wrap on #ASCO26! We're proud of our oncology progress. Our existing portfolio is focused on creating a positive impact and our R&D pipeline aims to bring more innovative medicines to patients. Watch our oncology leaders, Hesham Abdullah and Ali Çimen, reflect on an inspiring weekend ⤵️ 000
GSK @gsk.com · 31/05/2026Have you heard of antibody-drug conjugates (ADCs)? These innovative therapies are becoming a promising option for more targeted cancer treatment, and our researchers are at the forefront of advancing their potential. Curious to learn more? 🔗 Hear from our leading experts: bit.ly/42ZvUTd 000
GSK @gsk.com · 28/05/2026#News for #investors & #media: Today at #EASLCongress, we’re presenting results from a phase III trial in chronic hepatitis B, a disease affecting approximately 240 million people globally. Learn more: gsk.to/3S77yoc 021
GSK @gsk.com · 26/05/2026#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/49hUlis 010
GSK @gsk.com · 18/05/2026#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: gsk.to/4eSI47M 000
GSK @gsk.com · 06/05/2026At our recent virtual event with Washington Post Live Hesham Abdullah, Global Head of Oncology R&D at GSK and Peter Lee, President of Microsoft Science, shared how cutting-edge technology is fuelling the mission to improve outcomes for people living with cancer – and to do so more quickly. 100
GSK @gsk.com · 06/05/2026#News for #investors and #media: At #ATS2026, we’ll be presenting data across 33 abstracts to highlight our research as we work to redefine respiratory care. gsk.to/4nmDlx9 000
GSK @gsk.com · 29/04/2026#Investors and #Media: Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures in our Q1 2026 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. www.gsk.com/en-gb/invest... 010
GSK @gsk.com · 29/04/2026News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026 ⤵️ Find out more: gsk.to/4ePgo3m $GSK #earnings 110
GSK @gsk.com · 28/04/2026#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review by US FDA. Learn more: gsk.to/3Qz28Sq 021
GSK @gsk.com · 27/04/2026#News for #investors and #media: Today we announced that our investigational liver therapy received US FDA Breakthrough Therapy and EMA Priority Medicine (PRIME) regulatory designations for metabolic dysfunction-associated steatohepatitis (MASH). Find out more: gsk.to/3Qp3P4V 010
GSK @gsk.com · 23/04/2026Symptoms of CRSwNP, like nasal obstruction, facial pain and sleep disturbances, can greatly impact a person’s quality of life. Today, on #WorldCRSwNPDay, we’re reinforcing our commitment to improving patient outcomes. See how: gsk.to/4twp830 000
GSK @gsk.com · 20/04/2026#News for #Investors and #Media China’s National Medical Products Administration (NMPA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: gsk.to/3QPIamj 000
GSK @gsk.com · 15/04/2026#News for #investors and #media: Today we announced the completion of our acquisition of 35Pharma Inc., adding to our Respiratory, Immunology & Inflammation pipeline. Find out more: gsk.to/4ccpQw3 011
GSK @gsk.com · 12/04/2026#News for #Investors and #Media: Today at #SGO2026, we’re presenting new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: gsk.to/3Q00jh7 000
GSK @gsk.com · 10/04/2026We're at #SGO26! With an innovative pipeline, we’re building on our strong foundations in oncology research to improve how people live with cancer 🧡 Join us as we share more about our vision for transforming cancer care. 🔗 Learn more: bit.ly/4dz0866 100
GSK @gsk.com · 10/04/2026Antibody-drug conjugates (ADCs) - what exactly are they? ➡️ Swipe to find out how this innovation technology works to target cancer cells. 🔗 And dive deeper into the world of ADCs in our latest Behind the Science article: bit.ly/41kHkjL 010
GSK @gsk.com · 08/04/2026#News for #Media and #Investors: China's National Medical Products Administration (NMPA) has approved our new therapy for people living with chronic rhinosinusitis with nasal polyps (CRSwNP). For more information, visit: bit.ly/43sHkQ0 000
